PMID- 12207594
OWN - NLM
STAT- MEDLINE
DCOM- 20021122
LR  - 20190704
IS  - 0007-0963 (Print)
IS  - 0007-0963 (Linking)
VI  - 147
IP  - 3
DP  - 2002 Sep
TI  - A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in 
      adults with severe atopic dermatitis.
PG  - 518-22
AB  - BACKGROUND: There is a need for alternative therapy in severe adult atopic 
      dermatitis (AD). Intravenous immunoglobulin (IVIG) treatment has been shown to be 
      beneficial in a few open observations, but evidence of effectiveness is still 
      lacking. OBJECTIVE: To investigate whether treatment with IVIG is effective in 
      adults with severe AD. METHODS: In a randomized evaluator-blinded trial, 10 
      patients with severe AD were randomized to immediate or delayed (by 1 month) 
      treatment with IVIG 2 g kg-1. Patients received an 8-h infusion of 1 g kg-1 daily 
      for two consecutive days. They were assessed clinically at days 15, 30, 60 and 
      90. The primary efficacy criterion was measurement of the severity scoring of AD 
      (SCORAD) index at day 30. RESULTS: The SCORAD values were not significantly 
      different between the two groups at day 30. Similarly, global evaluation of 
      disease severity by patients did not show any clinically significant change at 
      day 30. In the cohort of 10 patients, the mean percentage decrease in SCORAD as 
      compared with baseline was, respectively, 15%[95% confidence interval (CI) 6-24%] 
      and 22% (95% CI 5-39%) at 30 and 60 days after IVIG infusion. CONCLUSIONS: IVIG 
      treatment was not associated with clinically significant improvement of AD signs 
      and symptoms in this randomized study. Although this study may have been too 
      small to detect a beneficial effect in a small subset of patients, the results do 
      not support the common use of IVIG in refractory AD.
FAU - Paul, C
AU  - Paul C
AD  - Department of Dermatology, Saint Louis University Hospital, 1 avenue Claude 
      Vellefaux, 75475 Paris, France.
FAU - Lahfa, M
AU  - Lahfa M
FAU - Bachelez, H
AU  - Bachelez H
FAU - Chevret, S
AU  - Chevret S
FAU - Dubertret, L
AU  - Dubertret L
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
CIN - Br J Dermatol. 2003 Jun;148(6):1284-5; author reply 1285-6. PMID: 12828775
MH  - Adult
MH  - Dermatitis, Atopic/*therapy
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Male
MH  - Prospective Studies
MH  - Severity of Illness Index
MH  - Single-Blind Method
MH  - Treatment Outcome
EDAT- 2002/09/05 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/09/05 10:00
PHST- 2002/09/05 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/09/05 10:00 [entrez]
AID - 4833 [pii]
AID - 10.1046/j.1365-2133.2002.04833.x [doi]
PST - ppublish
SO  - Br J Dermatol. 2002 Sep;147(3):518-22. doi: 10.1046/j.1365-2133.2002.04833.x.